scPharmaceuticals Inc. (SCPH)
scPharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burlington, MA, US. The stock last traded at $5.67, up 0.00% on the session, giving a market capitalisation of $302.2M. On trailing twelve-month figures it carries a trailing P/E of -7.99, a net margin of -135.9%. Its beta of 0.30 implies it has historically moved less than the broad market.
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.
scPharmaceuticals Inc. is most often compared with the following Healthcare names: